409 related articles for article (PubMed ID: 30611527)
61. Dilemma of first line regimens in metastatic pancreatic adenocarcinoma.
Ghosn M; Ibrahim T; Assi T; El Rassy E; Kourie HR; Kattan J
World J Gastroenterol; 2016 Dec; 22(46):10124-10130. PubMed ID: 28028360
[TBL] [Abstract][Full Text] [Related]
62. The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma.
Ghaneh P; Kleeff J; Halloran CM; Raraty M; Jackson R; Melling J; Jones O; Palmer DH; Cox TF; Smith CJ; O'Reilly DA; Izbicki JR; Scarfe AG; Valle JW; McDonald AC; Carter R; Tebbutt NC; Goldstein D; Padbury R; Shannon J; Dervenis C; Glimelius B; Deakin M; Anthoney A; Lerch MM; Mayerle J; Oláh A; Rawcliffe CL; Campbell F; Strobel O; Büchler MW; Neoptolemos JP;
Ann Surg; 2019 Mar; 269(3):520-529. PubMed ID: 29068800
[TBL] [Abstract][Full Text] [Related]
63. Toxicity of chemotherapy regimens in advanced and metastatic pancreatic cancer therapy: A network meta-analysis.
Wang XF; Huang WF; Nie J; Zhou Y; Tan DW; Jiang JH
J Cell Biochem; 2018 Jul; 119(7):5082-5103. PubMed ID: 28681936
[TBL] [Abstract][Full Text] [Related]
64. A treatment landscape in evolution: new strategies, guidelines, and therapeutic advances for metastatic pancreatic adenocarcinoma.
Bekaii-Saab T
Clin Adv Hematol Oncol; 2018 Sep; 16 Suppl 17(9):5-7. PubMed ID: 30807560
[No Abstract] [Full Text] [Related]
65. Could the combination of Nab-paclitaxel plus gemcitabine salvage metastatic pancreatic adenocarcinoma after folfirinox failure? A single institutional retrospective analysis.
El Rassy E; Assi T; El Karak F; Ghosn M; Kattan J
Clin Res Hepatol Gastroenterol; 2017 Mar; 41(2):e26-e28. PubMed ID: 28215539
[No Abstract] [Full Text] [Related]
66. Attenuated FOLFIRINOX in the salvage treatment of gemcitabine-refractory advanced pancreatic cancer: a phase II study.
Kim JH; Lee SC; Oh SY; Song SY; Lee N; Nam EM; Lee S; Hwang IG; Lee HR; Lee KT; Bae SB; Kim HJ; Jang JS; Lim DH; Lee HW; Kang SY; Kang JH
Cancer Commun (Lond); 2018 Jun; 38(1):32. PubMed ID: 29866170
[TBL] [Abstract][Full Text] [Related]
67. Updates on first-line therapy for metastatic pancreatic adenocarcinoma.
Marks E; Saif MW; Jia Y
JOP; 2014 Mar; 15(2):99-102. PubMed ID: 24618427
[TBL] [Abstract][Full Text] [Related]
68. Treatment of metastatic pancreatic adenocarcinoma: a review.
Thota R; Pauff JM; Berlin JD
Oncology (Williston Park); 2014 Jan; 28(1):70-4. PubMed ID: 24683721
[TBL] [Abstract][Full Text] [Related]
69. 5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with metastatic pancreatic adenocarcinoma.
Assaf E; Verlinde-Carvalho M; Delbaldo C; Grenier J; Sellam Z; Pouessel D; Bouaita L; Baumgaertner I; Sobhani I; Tayar C; Paul M; Culine S
Oncology; 2011; 80(5-6):301-6. PubMed ID: 21778770
[TBL] [Abstract][Full Text] [Related]
70. Post-gemcitabine therapy for patients with advanced pancreatic cancer - A comparative review of randomized trials evaluating oxaliplatin- and/or irinotecan-containing regimens.
Vogel A; Ciardiello F; Hubner RA; Blanc JF; Carrato A; Yang Y; Patel DA; Ektare V; de Jong FA; Gill S
Cancer Treat Rev; 2016 Nov; 50():142-147. PubMed ID: 27676174
[TBL] [Abstract][Full Text] [Related]
71. Gemcitabine plus nab-paclitaxel vs. FOLFIRINOX for patients with advanced pancreatic cancer.
Tahara J; Shimizu K; Otsuka N; Akao J; Takayama Y; Tokushige K
Cancer Chemother Pharmacol; 2018 Aug; 82(2):245-250. PubMed ID: 29846765
[TBL] [Abstract][Full Text] [Related]
72. Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial.
Gourgou-Bourgade S; Bascoul-Mollevi C; Desseigne F; Ychou M; Bouché O; Guimbaud R; Bécouarn Y; Adenis A; Raoul JL; Boige V; Bérille J; Conroy T
J Clin Oncol; 2013 Jan; 31(1):23-9. PubMed ID: 23213101
[TBL] [Abstract][Full Text] [Related]
73. Any progress in the management of advanced pancreatic cancer? Highlights from the 45th ASCO annual meeting. Orlando, FL, USA. May 29-June 2, 2009.
Li J; Saif MW
JOP; 2009 Jul; 10(4):361-5. PubMed ID: 19581735
[TBL] [Abstract][Full Text] [Related]
74. Benefit of Gemcitabine/Nab-Paclitaxel Rescue of Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma After Early Failure of FOLFIRINOX.
Vreeland TJ; McAllister F; Javadi S; Prakash LR; Fogelman DR; Ho L; Varadhachary G; Aloia TA; Vauthey JN; Lee JE; Kim MP; Katz MHG; Tzeng CD
Pancreas; 2019 Jul; 48(6):837-843. PubMed ID: 31210666
[TBL] [Abstract][Full Text] [Related]
75. 5-Fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with advanced pancreatic cancer who have progressed on gemcitabine-based therapy.
Lee MG; Lee SH; Lee SJ; Lee YS; Hwang JH; Ryu JK; Kim YT; Kim DU; Woo SM
Chemotherapy; 2013; 59(4):273-9. PubMed ID: 24457620
[TBL] [Abstract][Full Text] [Related]
76. Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy - a multicenter, non-comparative, randomized, phase II trial (PANACHE01-PRODIGE48 study).
Schwarz L; Vernerey D; Bachet JB; Tuech JJ; Portales F; Michel P; Cunha AS
BMC Cancer; 2018 Jul; 18(1):762. PubMed ID: 30041614
[TBL] [Abstract][Full Text] [Related]
77. Is there a role for second line therapy in advanced pancreatic cancer?
Choi M; Saif MW; Kim R
JOP; 2014 Mar; 15(2):106-9. PubMed ID: 24618429
[TBL] [Abstract][Full Text] [Related]
78. Class III β-Tubulin Expression Is of Value in Selecting nab -Paclitaxel and Gemcitabine as First-Line Therapy in Unresectable Pancreatic Cancer.
Kato A; Naitoh I; Naiki-Ito A; Hayashi K; Okumura F; Fujita Y; Sano H; Nishi Y; Miyabe K; Inoue T; Hirano A; Takada H; Yoshida M; Hori Y; Natsume M; Kato H; Takahashi S; Kataoka H
Pancreas; 2022 Apr; 51(4):372-379. PubMed ID: 35695793
[TBL] [Abstract][Full Text] [Related]
79. Clinical Outcomes of S-1 Monotherapy and Modified FOLFIRINOX Therapy after Gemcitabine plus Nab-paclitaxel Therapy in Unresectable Pancreatic Cancer.
Hino K; Nishina T; Numata Y; Asagi A; Inoue T; Yoshimatsu M; Sakaguchi C; Nakasya A; Nishide N; Kajiwara T; Terao T; Nadano S; Marui K; Okujima Y; Kokubu M; Imamura Y; Kanemitsu K; Koizumi M; Kumagi T; Hiasa Y; Hyodo I
Intern Med; 2022; 61(15):2255-2261. PubMed ID: 35908959
[TBL] [Abstract][Full Text] [Related]
80. 5-Fluorouracil/L-Leucovorin Plus Oxaliplatin (FOLFOX) Regimen as Salvage Chemotherapy for Patients with Unresectable Pancreatic Cancer Receiving Gemcitabine and Nab-Paclitaxel and 5-Fluorouracil/L-Leucovorin Plus Nanoliposomal Irinotecan: Preliminary Results from Clinical Practice.
Yamai T; Ikezawa K; Kawamoto Y; Hirao T; Higashi S; Daiku K; Maeda S; Abe Y; Urabe M; Kai Y; Takada R; Nakabori T; Uehara H; Ohkawa K
Curr Oncol; 2022 Apr; 29(4):2644-2649. PubMed ID: 35448190
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]